Global Ophthalmology Disorders Drug Market Growth (Status and Outlook) 2025-2031

According to this study, the global Ophthalmology Disorders Drug market size will reach US$ million by 2031.

Macular degeneration is a group of eye disease commonly found among children and adults. There are various types of macular degeneration affecting the teens such as Cone-Rod Dystrophy, Best disease, Stargardt disease, Corneal Dystrophy, and Fuch’s Dystrophy.Retinitis pigmentosa is generally inherited from a person"s parents. Mutations in one of more than 50 genes is involved.

United States market for Ophthalmology Disorders Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Ophthalmology Disorders Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Ophthalmology Disorders Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Ophthalmology Disorders Drug players cover Sanofi, Bayer, Bausch + Lomb, Novartis, Usher Syndrome, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Ophthalmology Disorders Drug Industry Forecast” looks at past sales and reviews total world Ophthalmology Disorders Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Ophthalmology Disorders Drug sales for 2025 through 2031. With Ophthalmology Disorders Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ophthalmology Disorders Drug industry.

This Insight Report provides a comprehensive analysis of the global Ophthalmology Disorders Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Ophthalmology Disorders Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ophthalmology Disorders Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ophthalmology Disorders Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ophthalmology Disorders Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Ophthalmology Disorders Drug market by product type, application, key players and key regions and countries.

Segmentation by Type:
Oral
Injection
External Use

Segmentation by Application:
Juvenile Macular Degeneration (Stargardt Disease)
Leber Congenital Amaurosis (LCA)
Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
Usher Syndrome
Retinitis Pigmentosa (Retinitis)

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi
Bayer
Bausch + Lomb
Novartis
Usher Syndrome
Takeda Pharmaceutical
Roche
Pfizer
Allergan
Gilead Sciences
Kubota Pharmaceutical
Alkeus Pharmaceuticals
Astellas Pharma
Ferrer Corporate
Amgen Inc
Editas Medicine Inc
ProQR Therapeutics NV
ReNeuron
Amarantus BioScience
Ocugen
ReGenX Biosciences
Sucampo Pharmaceuticals
Orphagen Pharmaceuticals
Okuvision
Second Sight Medical
Acucela
Stealth BioTherapeutics
Sun Pharma Advanced Research Company
AmpliPhi Biosciences
Applied Genetic Technologies
Asklepios BioPharmaceutical
Biovista
Spark Therapeutics
Caladrius Biosciences
Dompe Farmaceutici
Dormant Projects
Grupo Ferrer Internacional
ID Pharma
InFlectis BioScience
Ionis Pharmaceuticals
Ixchel Pharma
Khondrion
Mimetogen Pharmaceuticals
Mitotech
M's Science
Nanovector
SanBio

Please note: The report will take approximately 2 business days to prepare and deliver. Show more